| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Dec―18 |
Efficient production of fully active, SARS-CoV-2-priming, wildtype TMPRSS2 ectodomain via co-expression of HAI-2 allows for both auto- and cross-activation mechanisms |
Barbara Végh, Andrea Kocsis, József Dobó, Júlia Balczer, Bence Kiss, Gábor Pál, Péter Gál |
| 2 |
[GO] |
2024―May―07 |
Efficient overexpression and purification of SARS-CoV-2 Nucleocapsid proteins in Escherichia coli |
Emma L Brudenell, Manoj B Pohare, Domen Zafred, Janine Phipps, Hailey R Hornsby, John Darby, Junxiao Dai, Ellen Liggett, Kathleen Cain, Perdita Barran, Thushan I de Silva, Jon R Sayers |
| 3 |
[GO] |
2023―Aug―16 |
Are fibrinaloid microclots a cause of autoimmunity in Long Covid and other post-infection diseases? |
Douglas B. Kell, Etheresia Pretorius |
| 4 |
[GO] |
2023―May―31 |
Key Allosteric and Active Site Residues of SARS-CoV-2 3CLpro Are Promising Drug Targets |
Kenana Al Adem, Juliana C. Ferreira, Samar Fadl, Morad Mustafa, Wael M. Rabeh |
| 5 |
[GO] |
2022―Oct―07 |
Therapeutic potential of metal ions for COVID-19: insights from the papain-like protease of SARS-CoV-2 |
Cameron Lee Shetler, Juliana C. Ferreira, Thyago H. S. Cardoso, Edson M.A. Silva, Nitin K. Saksena, Wael M. Rabeh |
| 6 |
[GO] |
2022―Sep―02 |
The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications |
Douglas B. Kell, Etheresia Pretorius |
| 7 |
[GO] |
2022―Apr―05 |
Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity |
Gavin D Garland, Robert F Harvey, Thomas E Mulroney, Mie Monti, Stewart Fuller, Richard Haigh, Pehuén Pereyra Gerber, Michael R Barer, Nicholas J Matheson, Anne E Willis |
| 8 |
[GO] |
2022―Mar―04 |
Programmed cell death: the pathways to severe COVID-19? |
Stefanie M. Bader, James P. Cooney, Marc Pellegrini, Marcel Doerflinger |
| 9 |
[GO] |
2022―Feb―23 |
A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications |
Douglas B. Kell, Gert Jacobus Laubscher, Etheresia Pretorius |
| 10 |
[GO] |
2021―Sep―24 |
Diversity of ACE2 and its interaction with SARS-CoV-2 receptor binding domain |
Jessie L Gan, Ruiqi Huang, Abigail Kelley, Gabrielle Warner, Duncan McGregor, Vaughn V. Smider |
| 11 |
[GO] |
2021―Aug―13 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp14/nsp10 exoribonuclease |
Berta Canal, Allison W. McClure, Joseph F. Curran, Mary Wu, Rachel Ulferts, Florian Weissmann, Jingkun Zeng, Agustina P. Bertolin, Jennifer C. Milligan, Souradeep Basu, Lucy S. Drury, Tom D. Deegan, Ryo Fujisawa, Emma L. Roberts, Clovis Basier, Karim Labib, Rupert Beale, Michael Howell, John F.X. Diffley |
| 12 |
[GO] |
2021―Jul―01 |
Author's overview: identifying SARS-CoV-2 antiviral compounds |
John F.X. Diffley |
| 13 |
[GO] |
2021―Jul―01 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease |
Chew Theng Lim, Kang Wei Tan, Mary Wu, Rachel Ulferts, Lee A. Armstrong, Eiko Ozono, Lucy S. Drury, Jennifer C. Milligan, Theresa U. Zeisner, Jingkun Zeng, Florian Weissmann, Berta Canal, Ganka Bineva-Todd, Michael Howell, Nicola O'Reilly, Rupert Beale, Yogesh Kulathu, Karim Labib, John F.X. Diffley |
| 14 |
[GO] |
2021―Jul―01 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase |
Souradeep Basu, Tiffany Mak, Rachel Ulferts, Mary Wu, Tom Deegan, Ryo Fujisawa, Kang Wei Tan, Chew Theng Lim, Clovis Basier, Berta Canal, Joseph F. Curran, Lucy S. Drury, Allison W. McClure, Emma L. Roberts, Florian Weissmann, Theresa U. Zeisner, Rupert Beale, Victoria H. Cowling, Michael Howell, Karim Labib, John F.X. Diffley |
| 15 |
[GO] |
2021―Jul―01 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase |
Jingkun Zeng, Florian Weissmann, Agustina P. Bertolin, Viktor Posse, Berta Canal, Rachel Ulferts, Mary Wu, Ruth Harvey, Saira Hussain, Jennifer C. Milligan, Chloe Roustan, Annabel Borg, Laura McCoy, Lucy S. Drury, Svend Kjaer, John McCauley, Michael Howell, Rupert Beale, John F.X. Diffley |
| 16 |
[GO] |
2021―Jul―01 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase |
Agustina P. Bertolin, Florian Weissmann, Jingkun Zeng, Viktor Posse, Jennifer C. Milligan, Berta Canal, Rachel Ulferts, Mary Wu, Lucy S. Drury, Michael Howell, Rupert Beale, John F.X. Diffley |
| 17 |
[GO] |
2021―Jul―01 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp5 main protease |
Jennifer C. Milligan, Theresa U. Zeisner, George Papageorgiou, Dhira Joshi, Christelle Soudy, Rachel Ulferts, Mary Wu, Chew Theng Lim, Kang Wei Tan, Florian Weissmann, Berta Canal, Ryo Fujisawa, Tom Deegan, Hema Nagaraj, Ganka Bineva-Todd, Clovis Basier, Joseph F. Curran, Michael Howell, Rupert Beale, Karim Labib, Nicola O'Reilly, John F.X. Diffley |
| 18 |
[GO] |
2021―Jul―01 |
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease |
Berta Canal, Ryo Fujisawa, Allison W. McClure, Tom D. Deegan, Mary Wu, Rachel Ulferts, Florian Weissmann, Lucy S. Drury, Agustina P. Bertolin, Jingkun Zeng, Rupert Beale, Michael Howell, Karim Labib, John F.X. Diffley |
| 19 |
[GO] |
2021―Jul―01 |
An all-out assault on SARS-CoV-2 replication |
Ronald T. Hay |
| 20 |
[GO] |
2021―Jan―14 |
The role of chemical biology in the fight against SARS-CoV-2 |
George M. Burslem |
| 21 |
[GO] |
2020―Apr―29 |
Expanding our understanding of the role polyprotein conformation plays in the coronavirus life cycle |
Samantha Gildenhuys |
| 22 |
[GO] |
2020―Feb―21 |
Processing of the SARS-CoV pp1a/ab nsp7-10 region |
Boris Krichel, Sven Falke, Rolf Hilgenfeld, Lars Redecke, Charlotte Uetrecht |
|
